Targeting Sox17 in PAH

Presented at Genetics-inspired Therapeutics for PH by Chris Rhodes, Imperial College London

Summary

This video explores the role of SOX17 as a genetic driver of pulmonary arterial hypertension (PAH). It highlights how rare and common variants in SOX17 contribute to the disease by affecting pulmonary vascular development. It discusses potential drug development, identifying BX912 as a promising drug with the potential to reverse SOX17-related genetic changes.

Generated by AI, edited by PVRI